World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
49
Citations
9007
World Ranking
4341
National Ranking
1973

Overview

Ligia A. Pinto is affiliated with Leidos in the United States and has made significant contributions to the field of medicine with a specialization in epidemiology, infectious diseases, immunology, molecular biology, and oncology. Their research output includes 172 publications centered on these areas of study.

Their work prominently focuses on several main topics, including:

  • Cervical Cancer and HPV Research
  • Hepatitis B Virus Studies
  • SARS-CoV-2 and COVID-19 Research
  • SARS-CoV-2 detection and testing
  • COVID-19 Clinical Research Studies
  • Immunotherapy and Immune Responses
  • Animal Virus Infections Studies

Ligia A. Pinto has frequently published in the following venues:

  • Vaccine (8 publications)
  • Cancer Research (6 publications)
  • Human Vaccines & Immunotherapeutics (5 publications)
  • JNCI Journal of the National Cancer Institute (4 publications)
  • The Lancet Global Health (4 publications)

The scientist is also noted for collaboration with several frequent co-authors including Troy J. Kemp, Allan Hildesheim, Douglas R. Lowy, Rolando Herrero, and Carolina Porras.

Some recent significant papers include:

  • "Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial" (2020), published in JNCI Journal of the National Cancer Institute
  • "Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial" (2020), published in The Lancet Oncology
  • "Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial" (2022), published in The Lancet Global Health
  • "Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial" (2020), published in JNCI Journal of the National Cancer Institute
  • "SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response" (2020), published in Open Forum Infectious Diseases

Best Publications

  • Comprehensive control of human papillomavirus infections and related diseases.

    F. Xavier Bosch;Thomas R. Broker;David Forman;Anna Barbara Moscicki

  • T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation

    Sharon H Jackson;Satish Devadas;Satish Devadas;Jaeyul Kwon;Jaeyul Kwon;Ligia A Pinto

  • Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro

    Mario Clerici;Daniel R. Lucey;Jay A. Berzofsky;Ligia A. Pinto

  • Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers

    Meredith S. Shiels;Hormuzd A. Katki;Neal D. Freedman;Mark P. Purdue

  • ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids.

    L A Pinto;J Sullivan;J A Berzofsky;M Clerici

  • Cellular Immune Responses to Human Papillomavirus (HPV)-16 L1 in Healthy Volunteers Immunized with Recombinant HPV-16 L1 Virus-Like Particles

    Ligia A. Pinto;Jessica Edwards;Philip E. Castle;Clayton D. Harro

  • Circulating Inflammation Markers and Prospective Risk for Lung Cancer

    Meredith S. Shiels;Ruth M. Pfeiffer;Allan Hildesheim;Eric A. Engels

  • Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

    Francis J Dessy;Sandra L Giannini;Catherine A Bougelet;Troy J Kemp

  • Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

    Mahboobeh Safaeian;Carolina Porras;Yuanji Pan;Aimee Kreimer

  • Human papillomavirus vaccines--immune responses.

    Margaret Stanley;Ligia A. Pinto;Connie Trimble

  • HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

    Troy J. Kemp;Allan Hildesheim;Mahboobeh Safaeian;Joseph G. Dauner

  • Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.

    Aimée R Kreimer;Joshua N Sampson;Carolina Porras;John T Schiller

  • Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles

    Fatma M. Shebl;Ligia A. Pinto;Alfonso García-Piñeres;Alfonso García-Piñeres;Richard Lempicki

  • Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment

    Allan Hildesheim;Paula Gonzalez;Aimee R. Kreimer;Sholom Wacholder

  • Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women

    Alfonso J. García-Piñeres;Allan Hildesheim;Rolando Herrero;Matthew Trivett

  • Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies

    Aimée R. Kreimer;Rolando Herrero;Joshua N. Sampson;Carolina Porras

  • Evaluation of Multiplexed Cytokine and Inflammation Marker Measurements: a Methodologic Study

    Anil K. Chaturvedi;Troy J. Kemp;Ruth M. Pfeiffer;Angelique Biancotto

  • Noninfectious papilloma virus–like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27

    J. Mohamad Fakruddin;Richard A. Lempicki;Robert J. Gorelick;Jun Yang

  • Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

    Britton Trabert;Ligia Pinto;Patricia Hartge;Troy Kemp

  • Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

    Carolina Porras;Sabrina H. Tsang;Rolando Herrero;Diego Guillén

  • Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial

    Unknown

  • Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma

    M P Purdue;Q Lan;T J Kemp;A Hildesheim

  • Bivalent HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

    Ligia Pinto;Troy Kemp;Allan Hildesheim;Mahboobeh Safaeian

Frequent Co-Authors

Allan Hildesheim
Allan Hildesheim National Institutes of Health
Ruth M. Pfeiffer
Ruth M. Pfeiffer National Institutes of Health
Rolando Herrero
Rolando Herrero Costa Rican Agency for Biomedical Research, INCIENSA Foundation
John T. Schiller
John T. Schiller National Institutes of Health
Gene M. Shearer
Gene M. Shearer National Institutes of Health
Douglas R. Lowy
Douglas R. Lowy National Institutes of Health
Mark Schiffman
Mark Schiffman National Institutes of Health
Mark P. Purdue
Mark P. Purdue National Institutes of Health
Wim Quint
Wim Quint Erasmus University Rotterdam
Ann W. Hsing
Ann W. Hsing Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in exploring immunology alongside healthcare professions, there are several viable online degree options. Many students begin with foundational nursing education through online ADN programs for non nurses, which provide a fast track for individuals starting fresh in healthcare.

After building nursing credentials, professionals often look to specialize. Acute care nurse practitioner programs offer advanced training focused on critical and complex patient care, making them an excellent complement to immunology knowledge—especially for those managing immunocompromised patients.

For a quicker route through nursing education, many consider accelerated nursing programs near me. These programs cater to career changers or those seeking to expedite their BSN completion.

Finally, the nurse practitioner accelerated program option helps nurses advance rapidly into leadership roles by combining clinical expertise with advanced immunology-related applications. These pathways ensure well-rounded professionals ready to impact both healthcare delivery and immunological research.

Best Scientists Citing Ligia A. Pinto

Trending Scientists

Recently Published Articles